Glucagonlike Peptide 1-Based Therapies Associated With Acute Pancreatitis In StudyMain Category: Diabetes
Article Date: 25 Feb 2013
JAMA Internal Medicine Study Highlights
In a study by Sonal Singh, M.D., M.P.H., of The Johns Hopkins University School of Medicine, Baltimore, and colleagues, treatment with the glucagonlike peptide-1 (GLP-1)-based therapies sitagliptin and exenatide were associated with increased odds of hospitalization for acute pancreatitis in adults with type 2 diabetes mellitus. (Online First)
The population-based case-control study used a large administrative database of adults with type 2 diabetes. Researchers identified 1,269 hospitalized cases with acute pancreatitis and 1,269 matched controls. The average age of the patients was 52 years and almost 58 percent of them were men, according to the study.
"In summary, acute pancreatitis has significant morbidity and mortality. In this administrative database study of U.S. adults with type 2 diabetes mellitus, treatment with the GLP-1-based therapies sitagliptin and exenatide was associated with an increased risk of hospitalization for acute pancreatitis," the study concludes.
Original article posted on Medical News Today.
Articles not to be reproduced without permission of Medical News Today